At the last check on Thursday, Immunovant Inc.’s (NASDAQ:IMVT) stock was down -$0.08, moving down -0.39 percent to $20.52. The average number of shares traded per day over the past five days has been 917,541 shares. 2 times new highs have been achieved over the past 5 days, with a -$1.43 fall in that time frame. In the last twenty days, the average volume was 1,165,485, while in the previous 50 days, it was 1,143,476.
Since last month, IMVT stock retreated -0.24%. Shares of the company fell to $19.71 on 08/25/23, the lowest level in the past month. A 52-week high of $25.13 was reached on 07/19/23 after having rallying from a 52-week low of $4.26. Since the beginning of this year, IMVT’s stock price has risen by 15.61% or $2.83, and marked a new high 10 times. However, the stock has declined by -18.34% since its 52-week high.
Top 5 AI Stocks to Buy for 2023
The artificial intelligence (AI) revolution is already here. And it's about to change everything we know about everything.
According to Grand View Research, the global AI boom could grow from about $137 billion in 2022 to more than $1.81 trillion by 2030. And investors like you always want to get in on the hottest stocks of tomorrow. Here are five of the best ways to profit from the AI boom.
Click Here to Download the FREE Report.
Sponsored
IMVT stock investors should be aware that Immunovant Inc. (IMVT) stock had its last reported insider trading activity 22 days ago on Aug 30. Salzmann Peter, the Chief Executive Officer of the company, disposed of 56,774 shares for $22.02 on Aug 30. It resulted in a $1,250,338 divestment by the insider. Barnett Eva Renee sold 14,386 shares at an average price of $20.30 on Aug 24. The insider now owns 335,477 shares following the transaction. On Aug 24, Chief Development Officer Butchko Julia G. sold 12,333 shares at $20.30 apiece. The transaction was valued at $250,360.
Financial Health
In the three months ended June 29, Immunovant Inc.’s quick ratio stood at 6.80, while its current ratio was 6.80, showing that the company is able to pay off its debt.
According to the earnings report, the company had a higher net income in the recent quarter than it did in the previous quarter. While analysts expected Immunovant Inc. to report -$0.45 quarterly earnings, the actual figure was -$0.57 per share, beating the consensus estimate by -26.70%. During the quarter, the company generated -$78.42 million in EBITDA. The liabilities of Immunovant Inc. were 51.36 million at the end of its most recent quarter ended June 29, and its total debt was $0.92 million. The value of shareholders’ equity is $130.67 million.
Technical Picture
This quick technical analysis looks at Immunovant Inc.’s (IMVT) price momentum. With a historical volatility rate of 26.64%, the RSI 9-day stood at 34.54% on 20 September.
With respect to its five-day moving average, the current Immunovant Inc. price is down by -6.50% percent or -$1.43. At present, IMVT shares trade +1.78% above its 20-day simple moving average and +27.51% percent above its 100-day simple moving average. However, the stock is currently trading approximately +5.54% above its SMA50 and +40.19% above its SMA200.
Stochastic coefficient K was 8.56% and Stochastic coefficient D was 17.58%, while ATR was 1.07. Given the Stochastic reading of 12.97% for the 14-day period, the RSI (14) reading has been calculated as 41.13%. As of today, the MACD Oscillator reading stands at -0.74, while the 14-day reading stands at -1.30.
Analyst Ratings
BofA Securities launched its rating on Immunovant Inc. (NASDAQ: IMVT) to a Buy in a note to investors on May 01, 2023. Immunovant Inc. (IMVT) has been rated Buy by analysts. According to 0 brokerage firms, IMVT is a sell, and 1 firms recommend it is a Hold. There are 0 analysts who say the stock is underweight. A total of 0 analysts rate Immunovant Inc. stock as buy, with 12 recommending it as overweight.
With a median target price of $31.00, the current consensus forecast for the stock is $28.00 – $34.00. Based on these forecasts, analysts predict Immunovant Inc. (IMVT) will achieve an average price target of $31.08.
